Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.
Pesenti C
Eur J Cancer. 2022 Jun 14;171:85-95. doi: 10.1016/j.ejca.2022.05.005
Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations.
Mannarino L
Cell Death Dis. 2022 Jul 15;13(7):612. doi: 10.1038/s41419-022-05073-4
Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer.
Paracchini L
Cancers (Basel). 2022 Jul 29;14(15)doi: 10.3390/cancers14153697
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
Capoluongo ED
ESMO Open. 2022 Sep 23;7(5):100585. doi: 10.1016/j.esmoop.2022.100585
A comprehensive investigation of histotype-specific microRNA and their variants in Stage I epithelial ovarian cancers.
Velle A
Int J Cancer. 2023 Jan 17;152(9):1989-2001. doi: 10.1002/ijc.34408
Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity.
Mantovani A
Int J Cancer. 22(6):741-6.
Regulation of the macrophage content of neoplasms by chemoattractants.
Bottazzi B
Science. 220(4593):210-2.
Prostacyclin synthesis induced in vascular cells by interleukin-1.
Rossi V
Science. 229(4709):174-6.
Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate.
Bussolino F
Nature. 337(6206):471-3.
Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.
Colotta F
Science. 261(5120):472-5.